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Positive association between plasma homocysteine level and chronic kidney
disease
Abstract

BACKGROUND:
Increasing experimental evidence, including recently developed animal models, supports a role for
homocysteine in the development of chronic kidney disease (CKD). However, relatively few clinical/
epidemiological studies have examined this hypothesis in humans. We examined the relationship
between plasma homocysteine level and CKD in a population-based study of older Australians.

METHODS:
Community-based study (1992-1994) among 2,609 individuals (58.6% women), aged 49-98 years, free of
clinical cardiovascular disease in the Blue Mountains region, west of Sydney, Australia. The main
outcome-of-interest was CKD (n = 461), defined as estimated glomerular filtration rate of <60 ml>/min/
1.73 m(2).

RESULTS:
Higher plasma homocysteine levels were positively associated with CKD, independent of smoking, body
mass index, diabetes mellitus, hypertension, cholesterol levels, and other confounders. The multivariable
odds ratio (OR; 95% confidence intervals, CI) comparing quartile 4 of plasma homocysteine (>14
micromol/l) to quartile 1 (< or =9 micromol/l) was 10.44 (6.99-15.60), p-trend <0.0001. This association
persisted in both men and women separately. The results were also consistent in subgroup analyses by
categories of diabetes mellitus and hypertension.

CONCLUSIONS:
Higher plasma homocysteine levels are associated with CKD in a community-based sample of older
Australians. This association appeared to be independent of diabetes mellitus and hypertension.
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Abstract
Background: Increasing experimental evidence, including
recently developed animal models, supports a role for homocysteine in the development of chronic kidney disease
(CKD). However, relatively few clinical/epidemiological studies have examined this hypothesis in humans. We examined
the relationship between plasma homocysteine level and
CKD in a population-based study of older Australians.
Methods: Community-based study (1992–1994) among
2,609 individuals (58.6% women), aged 49–98 years, free of
clinical cardiovascular disease in the Blue Mountains region,
west of Sydney, Australia. The main outcome-of-interest was
CKD (n = 461), defined as estimated glomerular filtration rate
of !60 ml/min/1.73 m2. Results: Higher plasma homocysteine levels were positively associated with CKD, independent of smoking, body mass index, diabetes mellitus, hypertension, cholesterol levels, and other confounders. The
multivariable odds ratio (OR; 95% confidence intervals, CI)
comparing quartile 4 of plasma homocysteine (114 mol/l)
to quartile 1 (^9 mol/l) was 10.44 (6.99–15.60), p-trend
!0.0001. This association persisted in both men and women
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separately. The results were also consistent in subgroup
analyses by categories of diabetes mellitus and hypertension. Conclusions: Higher plasma homocysteine levels are
associated with CKD in a community-based sample of older
Australians. This association appeared to be independent of
diabetes mellitus and hypertension.
Copyright © 2008 S. Karger AG, Basel

Introduction

End-stage renal disease (ESRD) is an important public
health problem. There were estimated to be approximately 470,000 patients with ESRD in the United States in
2004 [1], and based on earlier data an estimated additional 8 million US adults have chronic kidney disease (CKD),
defined as a glomerular filtration rate (GFR) of !60 ml/
min/1.73 m2, who are at risk of progression to ESRD and
its attendant complications [2, 3]. It is therefore important to identify factors related to CKD, a kidney disease
stage earlier in the continuum at which prevention/control of disease progression is more applicable.
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Homocysteine is a sulfur-containing amino acid
formed during the metabolism of the essential amino
acid methionine [4]. Previous epidemiologic studies have
reported an association between plasma homocysteine
levels and atherosclerotic vascular disease [4–6], shown
to be a predictor of subsequent CKD [7]. Studies have also
reported an association between plasma homocysteine
and hypertension [8, 9], another strong, independent predictor of CKD [10]. Homocysteine may directly cause renal vascular damage through the production of reactive
oxygen species, effects on vascular smooth muscle cells,
endothelial injury, reduction in plasma and tissue interstitium adenosine levels, and mesangial cell proliferation
and apoptosis [4, 11–16]. Experimental animal models of
homocysteine-induced glomerular damage have also
been developed [14, 17]. However, few studies have examined the putative association between elevated plasma
homocysteine and CKD [18–20]. While one large study
reported a positive association between homocysteine
and CKD in a Japanese population sample [18], two earlier studies did not find an independent association [19,
20]. In particular, it is not clear if plasma homocysteine is
related to CKD independent of hypertension and diabetes mellitus, two of its strong predictors. In this context,
we examined the association between plasma homocysteine levels and CKD in a population-based sample of
older Australian adults after adjusting for the major confounders and stratifying by hypertension and diabetes
mellitus status.
Methods
The current report is based on the second Blue Mountains Eye
Study (BMES II, 1997–2000), a population-based study of participants aged 649 years, living in two postcodes of the Blue
Mountains region, west of Sydney, Australia, which has studied
age-related eye diseases and other health outcomes in an older
urban Australian population. Details of the study methods have
previously been described [21]. In brief, this cross-sectional survey (BMES II, 1997–2000) consisted of 3,509 participants. It included 2,335 participants (75.1% survivors from the baseline survey, BMES I, 1992–1994) plus an additional 1,174 participants
(identified in a repeat door-to-door census, 1999–2000) who had
become eligible by moving into the area or into the age bracket of
the original survey. The Blue Mountains population is representative of the Australian population. This study followed the recommendations of the Declaration of Helsinki, was approved by the
Western Sydney Area Health Service Human Research Ethics
Committee, and written, informed consent was obtained from all
participants.
The examination protocols involved measurement of weight,
height, systolic and diastolic blood pressures by a trained interviewer, and administration of a standardized questionnaire col-
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lecting information regarding demographic characteristics, cigarette smoking, alcohol intake, physical activity, and past medical
history.
Fasting blood specimens were drawn from 2,961 participants
(84.4%), centrifuged onsite and then couriered the same day to
Westmead Hospital, Sydney, Australia, for hematology and clinical biochemistry assessment. Plasma total homocysteine was determined using the fluorescent polarization immunoassay method on an IMx Analyzer. This system correlates well with HPLC
and gas chromatography-mass spectrometry assay methods [22].
Serum folate and vitamin B12 assays were performed using the
competitive-binding assay method on a Beckman-Access analyzer. White blood cell (WBC) count was determined using a Coulter
counter method. Total cholesterol, high-density lipoprotein cholesterol and triglyceride were measured on a Reflotron reflectance
photometric analyzer (Boehringer Mannheim Diagnostics [currently Roche Diagnostics], Germany). Fasting plasma glucose was
measured using the hexokinase method.
Age was defined as age at the baseline examination; education
was categorized into beyond high school, high school, and below
high school, and body mass index (BMI) was calculated as weight
(kg) divided by height squared (m2). Diabetes status was categorized using the American Diabetes Association criteria as follows:
diabetes = diagnosis by a physician and use of diabetic medications or fasting glucose levels at least 7.0 mmol/l (126 mg/dl); fasting hyperglycemia = fasting glucose levels 6.1 mmol/l (110 mg/dl)
or above but less than 7.0 mmol/l (126 mg/dl), and normoglycemia = fasting glucose levels below 6.1 mmol/l (110mg/dl). Cigarette smoking was categorized into current (current smoker or had
stopped smoking !12 months before the study examination), former (positively answered to ‘have you ever smoked regularly before?’ and had stopped smoking at least 12 months before the study
examination), and never smoker. Alcohol intake was categorized
as nondrinker, !once/week, 1–6 days/week, 1–2 drinks/day, 3 or
more drinks/day, and don’t know/missing. Physical inactivity (yes,
no) was categorized as answering negatively to ‘have you participated in any recreational exercise/walk in the last 2 weeks?’.
Details of blood pressure measurement and prevalence of hypertension in this older Australian community have been described previously [23]. Briefly, systolic and diastolic blood pressure was recorded by trained observers from the right arm with a
mercury sphygmomanometer using a cuff size appropriate for the
participant’s arm circumference, after they had been comfortably
seated for at least 10 min. Hypertension was defined according to
the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure as a systolic blood pressure of 140 mm Hg or higher, diastolic blood pressure 90 mm Hg or higher, or a combination of selfreported hypertension diagnosis and use of antihypertensive
medications [24].
Estimated GFR (eGFR) was the preferred measure of kidney
function in the current study. GFR was indirectly estimated using
the 4-variable Modification of Diet in Renal Disease Study equation [25]. The main outcome of interest was CKD, defined as an
eGFR of !60 ml/min/1.73 m2, consistent with the National Kidney Foundation Kidney Disease Outcomes Quality Initiative
6stage 2 chronic kidney disease [2].
To examine the association between plasma homocysteine
and hypertension and CKD of the 2,961 individuals who participated in the survey and had plasma homocysteine measured, the
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Table 1. Baseline characteristics of the cohort by quartiles of plasma homocysteine

Characteristics

Age, years
Women, %
Smoking
Current smoker, %
Former smoker, %
Alcohol use >3 drinks/day, %
Body mass index, kg/m2
Physically inactive, %
Diabetes mellitus, %
Serum total cholesterol, mmol/l
Serum triglyceride, mmol/l
Serum HDL cholesterol, mmol/l
Mean arterial pressure, mm Hg
Hypertension, %
eGFR, ml/min/1.73 m2
Chronic kidney disease (%)
Women only
Menopausal status, %
Hormone replacement therapy,%

p value

Quartile of plasma homocysteine (mol/l)
quartile 1
≤9.9 mol/l

quartile 2
10.0–11.9 mol/l

quartile 3
12.0–14.9 mol/l

quartile 4
>14.9 mol/l

62.280.3
73.5

65.380.3
56.4

67.580.4
52.6

70.980.3
47.1

<0.0001
<0.0001

9.4
35.7
11.8
27.280.2
16.0
9.0
5.880.04
1.5380.03
1.5380.01
104.281.1
68.2
81.780.6
4.7

9.0
38.3
15.7
27.380.2
20.4
9.7
5.880.04
1.5380.04
1.4680.02
106.881.2
77.2
75.980.7
11.7

9.7
40.2
16.2
27.980.2
24.0
10.3
5.980.04
1.5580.04
1.4780.02
106.581.4
79.7
71.580.8
20.5

9.7
46.7
18.9
28.080.2
29.0
10.6
5.980.04
1.5980.04
1.4580.02
108.281.2
82.0
65.080.7
37.2

0.97
0.0003
0.003
0.001
<0.0001
0.08
0.04
0.04
0.0006
0.03
<0.0001
<0.0001
<0.0001

93.5
45.3

95.9
41.8

97.3
30.5

98.4
25.6

0.003
<0.0001

The data presented are mean 8 SD values or row percentages. The p values are based on analysis of variance or the 2 test, as appropriate. eGFR = Estimated glomerular filtration rate based on the Modification of Diet in Renal Diseases study equation [25].

current study included 2,609 individuals free of clinical cardiovascular disease (1,080 men and 1,529 women) after excluding
those with missing systolic or diastolic blood pressure (n = 23),
serum creatinine levels (n = 10), and those with preexisting coronary heart disease (n = 223) or stroke (n = 96).
Statistical Methods
Baseline plasma homocysteine was categorized into quartiles
(^9.9, 10.0–11.9, 12.0–14.9, 114.9 mol/l) for the main analyses.
Homocysteine was also analyzed as a continuous variable (1 SD
[4.6 mol/l] increase). We used 2 test and analysis of variance to
compare the relationship of selected baseline characteristics by
plasma homocysteine quartiles. We were interested in two outcomes (1) hypertension and (2) CKD. We used multivariable logistic regression models to determine the odds ratio (OR) and
95% confidence interval (CI) of hypertension (n = 1,986) and
CKD (n = 461), controlling for potential confounders. We used 2
logistic regression models: an age- (years), sex-adjusted model,
and a multivariable-adjusted model, additionally adjusting for
smoking (never, former, current), alcohol intake (nondrinker,
!3 drinks/day, 63 drinks/day), BMI (kg/m2), physically inactive
(no, yes), diabetes mellitus (absent, present), hypertension (absent, present; adjusted in models with CKD as the outcome), mean
arterial blood pressure (mm Hg; adjusted in models with CKD as
the outcome), serum total cholesterol (mmol/l), HDL cholesterol
(mmol/l), triglyceride (mmol/l); among women we additionally
adjusted for menopausal status (absent, present), and ever use of
hormone replacement therapy (no, yes). Logistic regression mod-
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els with plasma homocysteine quartiles as ordered categories
scaled to the median for each quartile were used to assess trends
in OR. To examine the consistency of the association between homocysteine and CKD, we performed analyses within subgroups
of major confounders, including gender (men, women), hypertension (absent, present), and diabetes mellitus (absent, present). We
formally evaluated effect modification by including cross-product interaction terms in corresponding logistic regression models. We also performed several supplementary analyses. First, we
repeated the multivariable model additionally adjusting for serum
folate and vitamin B12 to examine if the observed association between plasma homocysteine and CKD was explained by these micronutrients. Second, to examine if the observed association between plasma homocysteine and CKD was explained by inflammation, we repeated the multivariable model additionally adjusting
for WBC count, a nonspecific marker of inflammation available
in the current study. SAS version 9.2 was used for all analyses.

Results

Among the 2,609 adults aged 649 years without clinical cardiovascular disease who were included in the current analysis, 1,986 subjects had hypertension and 461
had CKD. Table 1 presents the characteristics of the study
population by plasma homocysteine quartiles. Subjects
Kidney Blood Press Res 2008;31:55–62
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Table 2. Association between quartiles of plasma homocysteine and hypertension

Plasma homocysteine quartiles
Whole cohort (n = 2,609)
Quartile 1 (≤9.9 mol/l)
Quartile 2 (10.0–11.9 mol/l)
Quartile 3 (12.0–14.9 mol/l)
Quartile 4 (>14.9 mol/l)
p-trend
One SD (4.6 mol/l) increase

Number
at risk

Hypertension
cases

Age, sex
OR (95% CI)

Multivariable OR
(95% CI)a

802
658
487
662

547
508
388
543

2,609

1,986

1 (referent)
1.41 (1.11–1.80)
1.46 (1.11–1.94)
1.48 (1.12–1.96)
0.0034
1.29 (1.19–1.40)

1 (referent)
1.26 (0.98–1.63)
1.30 (0.97–1.74)
1.41 (1.06–1.88)
0.0178
1.23 (1.14–1.32)

OR = Odds ratio; 95% CI = 95% confidence interval.
a Estimated from a logistic regression model adjusted for age
(years), sex, smoking (never, former, current), alcohol intake
(nondrinker, <3 drinks/day, ≥3 drinks/day), body mass index (kg/
m2), physically inactive (no, yes), diabetes mellitus (absent, pres-

ent), serum total cholesterol (mmol/l), HDL cholesterol (mmol/l),
triglyceride (mmol/l). Among women we additionally adjusted
for menopausal status (absent, present), and ever use of hormone
replacement therapy (yes, no).

Table 3. Association between quartiles of plasma homocysteine and chronic kidney disease (CKD)

Plasma homocysteine quartiles
Whole cohort (n = 2,609)
Quartile 1 (≤9.9 mol/l)
Quartile 2 (10.0–11.9 mol/l)
Quartile 3 (12.0–14.9 mol/l)
Quartile 4 (>14.9 mol/l)
p-trend
One SD (4.6 mol/l) increase

Number
at risk

CKD cases

Age, sex
OR (95% CI)

Multivariable OR
(95% CI)a

802
658
487
662

38
77
100
246

2,609

461

1 (referent)
2.67 (1.78–3.99)
5.20 (3.51–7.70)
11.89 (8.28–17.07)
<0.0001
2.24 (2.00–2.51)

1 (referent)
2.54 (1.66–3.89)
4.68 (3.07–7.13)
10.44 (6.99–15.60)
<0.0001
2.12 (1.89–2.39)

OR = Odds ratio; 95% CI = 95% confidence interval.
a
Estimated from a logistic regression model adjusted for age
(years), sex, smoking (never, former, current), alcohol intake
(nondrinker, <3 drinks/day, ≥3 drinks/day), body mass index (kg/
m2), physically inactive (no, yes), diabetes mellitus (absent, pres-

ent), hypertension (absent, present), mean arterial blood pressure
(mm Hg), serum total cholesterol (mmol/l), HDL cholesterol
(mmol/l), triglyceride (mmol/l). Among women we additionally
adjusted for menopausal status (absent, present), and ever use of
hormone replacement therapy (yes, no).

with higher plasma homocysteine levels were more likely
to be older, former smokers, physically inactive, diabetic,
hypertensive, to have consumed 13 drinks of alcohol/day,
higher BMI, higher serum total cholesterol and triglyceride levels, lower HDL cholesterol levels, and higher mean
arterial pressure, and were less likely to be women than
those with lower plasma homocysteine. The mean eGFR
decreased and the prevalence of CKD increased with increasing plasma homocysteine quartiles.
In table 2, increasing plasma homocysteine quartiles
were positively associated with hypertension in both the
age- and sex-adjusted and multivariable-adjusted mod-

els; models evaluating trend in this association were also
statistically significant. When plasma homocysteine was
analyzed as a continuous variable (per SD increase) the
positive association with hypertension persisted. Also in
a related subsidiary analysis (data not shown in tables),
we confirmed that hypertension was positively associated
with CKD in the current study sample (multivariable OR
1.98, 95% CI 1.12–3.50).
Table 3 presents the OR of CKD by increasing plasma
homocysteine quartiles. Increasing plasma homocysteine quartiles were strongly positively associated with
CKD. When plasma homocysteine was analyzed as a con-
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Table 4. Association between quartiles of
plasma homocysteine and chronic kidney
disease (CKD) by gender

Plasma homocysteine quartiles
Men (n = 1,080)
Quartile 1 (≤9.9 mol/l)
Quartile 2 (10.0-11.9 mol/l)
Quartile 3 (12.0–14.9 mol/l)
Quartile 4 (>14.9 mol/l)
p-trend
Women (n = 1,529)
Quartile 1 (≤9.9 mol/l)
Quartile 2 (10.0–11.9 mol/l)
Quartile 3 (12.0–14.9 mol/l)
Quartile 4 (>14.9 mol/l)
p-trend

Number
at risk

CKD cases

Multivariable OR
(95% CI)a

212
287
231
350

4
9
16
83

1 (referent)
1.22 (0.36–4.19)
2.82 (0.90–8.95)
8.85 (3.05–25.70)
<0.0001

590
371
256
312

34
68
84
163

1 (referent)
2.85 (1.81–4.49)
5.29 (3.35–8.35)
11.12 (6.45–19.17)
<0.0001

OR = Odds ratio; 95% CI = 95% confidence interval.
a
Estimated from a logistic regression model adjusted for age (years), sex, smoking
(never, former, current), alcohol intake (nondrinker, <3 drinks/day, ≥3 drinks/day), body
mass index (kg/m2), physically inactive (no, yes), diabetes mellitus (absent, present), hypertension (absent, present), mean arterial blood pressure (mm Hg), serum total cholesterol (mmol/l), HDL cholesterol (mmol/l), triglyceride (mmol/l). Among women we additionally adjusted for menopausal status (absent, present), and ever use of hormone
replacement therapy (yes, no).

tinuous variable the positive association with CKD persisted.
Table 4 shows a clear positive association between
plasma homocysteine levels and CKD in both men and
women. Similarly, a consistent positive association was
observed in subgroup analyses after stratifying by the
presence of hypertension (table 5) or diabetes mellitus
(table 6).
We also performed several supplementary analyses.
First, we repeated the main analysis additionally adjusting for serum folate and vitamin B12 in the multivariable
model; the observed association between plasma homocysteine quartiles and CKD remained largely unchanged.
Compared to quartile 1 of plasma homocysteine, the
multivariable OR of CKD was 2.87 (95% CI 1.86–4.43) in
quartile 2; 5.62 (3.63–8.71) in quartile 3, and 13.72 (8.91–
21.13) in quartile 4 (p-trend ! 0.0001). Second, to examine if the observed association between plasma homocysteine and CKD was explained by inflammation, we repeated the multivariable model additionally adjusting for
WBC count; results remained similar here also. Compared to quartile 1 of plasma homocysteine, the multivariable OR of CKD was 2.53 (95% CI 1.65–3.88) in quartile 2; 4.65 (3.05–7.09) in quartile 3, and 10.36 (6.93–15.47)
in quartile 4 (p-trend ! 0.0001).

Homocysteine and Kidney Disease

Discussion

Higher plasma homocysteine levels were found to be
positively associated with CKD in a population-based
sample of older Australians, free of clinical cardiovascular disease. This association persisted after adjusting for
age, sex, BMI, smoking, alcohol intake, diabetes mellitus
and hypertension, and was consistently present in subgroup analysis by gender and important confounders.
The OR for the likely presence of CKD increased in a
dose-dependent manner with increasing quartiles of
plasma homocysteine. Our results contribute to the literature by suggesting that the putative plasma homocysteine–CKD association appears to be independent of
both diabetes mellitus and hypertension.
Our finding of a positive association between higher
plasma homocysteine levels and CKD shows high internal validity as shown by the magnitude of this association, its independence from related factors such as smoking, alcohol intake, BMI, diabetes mellitus, hypertension,
and serum lipid levels, the presence of a dose-response
trend, and the consistency of this association in subgroup
analyses by gender, and other important confounders.
Also, several lines of recent evidence suggest that an association between plasma homocysteine and renal vascular damage and subsequent CKD is plausible, including a
Kidney Blood Press Res 2008;31:55–62
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Table 5. Association between quartiles of

plasma homocysteine and chronic kidney
disease (CKD) by hypertension status

Plasma homocysteine quartiles
Normotensives (n = 623)
Quartile 1 (≤9.9 mol/l)
Quartile 2 (10.0–11.9 mol/l)
Quartile 3 (12.0–14.9 mol/l)
Quartile 4 (>14.9 mol/l)
p-trend
Hypertensives (n = 1,986)
Quartile 1 (≤9.9 mol/l)
Quartile 2 (10.0–11.9 mol/l)
Quartile 3 (12.0–14.9 mol/l)
Quartile 4 (>14.9 mol/l)
p-trend

Number
at risk

CKD cases

Multivariable OR
(95% CI)a

255
150
99
119

4
13
18
34

1 (referent)
5.91 (1.79–19.51)
15.63 (4.71–51.85)
23.16 (7.26–73.90)
<0.0001

547
508
388
543

34
64
82
212

1 (referent)
2.17 (1.37–3.44)
3.76 (2.38–5.92)
9.07 (5.89–13.96)
<0.0001

OR = Odds ratio; 95% CI = 95% confidence interval.
a
Estimated from a logistic regression model adjusted for age (years), sex, smoking
(never, former, current), alcohol intake (nondrinker, <3 drinks/day, ≥3 drinks/day), body
mass index (kg/m2), physically inactive (no, yes), diabetes mellitus (absent, present), hypertension (absent, present), mean arterial blood pressure (mm Hg), serum total cholesterol (mmol/l), HDL cholesterol (mmol/l), triglyceride (mmol/l). Among women we additionally adjusted for menopausal status (absent, present), and ever use of hormone
replacement therapy (yes, no). p-interaction for the cross-product interaction term between hypertension ! homocysteine quartiles = 0.56.

Table 6. Association between quartiles of

plasma homocysteine and chronic kidney
disease (CKD) by diabetes status

Plasma homocysteine quartiles

Number
at risk

Subjects without diabetes mellitus (n = 2,353)
730
Quartile 1 (≤9.9 mol/l)
594
Quartile 2 (10.0–11.9 mol/l)
437
Quartile 3 (12.0–14.9 mol/l)
592
Quartile 4 (>14.9 mol/l)
p-trend
Subjects with diabetes mellitus (n = 256)
72
Quartile 1 (≤9.9 mol/l)
64
Quartile 2 (10.0–11.9 mol/l)
50
Quartile 3 (12.0–14.9 mol/l)
70
Quartile 4 (>14.9 mol/l)
p-trend

CKD cases

Multivariable OR
(95% CI)a

34
67
87
209

1 (referent)
2.54 (1.62–3.99)
4.62 (2.96–7.21)
9.68 (6.33–14.81)
<0.0001

4
10
13
37

1 (referent)
2.70 (0.65–11.27)
5.46 (1.38–21.54)
23.16 (6.12–87.60)
<0.0001

OR = Odds ratio; 95% CI = 95% confidence interval.
a Estimated from a logistic regression model adjusted for age (years), sex, smoking
(never, former, current), alcohol intake (nondrinker, <3 drinks/day, ≥3 drinks/day), body
mass index (kg/m2), physically inactive (no, yes), diabetes mellitus (absent, present), hypertension (absent, present), mean arterial blood pressure (mm Hg), serum total cholesterol (mmol/l), HDL cholesterol (mmol/l), triglyceride (mmol/l). Among women we additionally adjusted for menopausal status (absent, present), and ever use of hormone
replacement therapy (yes, no). p-interaction for the cross-product interaction term between diabetes ! homocysteine quartiles = 0.22.
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role of homocysteine in the production of reactive oxygen
species, effects on vascular smooth muscle cells, endothelial injury, reduction in plasma and tissue interstitium
adenosine levels, and mesangial cell proliferation and
apoptosis [4, 11–16]. Furthermore, experimental animal
models of homocysteine-induced glomerular damage
have recently been developed [14, 17].
However, relatively few epidemiological studies to date
have examined the putative association between plasma
homocysteine levels and CKD [18–20], and several important questions regarding this association need further
clarification. First, while one large study reported a positive association between homocysteine and CKD [18],
two earlier studies did not confirm this association among
those without diabetes [19, 20]. In the current study, the
association between plasma homocysteine and CKD was
present both among those with or without diabetes mellitus, suggesting an association independent of diabetes.
Second, hypertension is a strong, independent predictor
of CKD [10]. As plasma homocysteine is related to hypertension in the current study (table 2) as well as in previous
reports [8, 9], confounding by hypertension/high blood
pressure needs to be considered in the observed association with CKD. In the current study, the homocysteine–
CKD association appeared to be independent of hypertension based on results in the stratified analysis, and was
present even after adjusting for mean arterial pressure in
the multivariable model.
The main advantages of our study include its large
sample size, stable general population sample base, avail-

ability of rich covariate/confounder information, and the
use of standardized protocols for exposure and outcome
assessment. The main study limitation is the cross-sectional nature of the current study which precludes conclusions regarding the temporal nature of the association
between plasma homocysteine and CKD. It is possible
that at least part of the observed association is due to reverse causality, including plasma homocysteine elevations secondary to reduced renal clearance, and to disruptions in the normal extrarenal homocysteine metabolism involving unidentified uremic inhibitory substances
[26]. Also, blood pressure levels were based on a single
reading in the survey. This could have resulted in slight
misclassification of hypertension status (likely to be overestimation). However, since we also adjusted for mean
arterial pressure in the multivariable models, the effect of
hypertension status misclassification on the homocysteine–CKD association is likely to be minimal.
In conclusion, higher plasma homocysteine levels were
found to be positively associated with prevalent CKD in
a population-based sample of older Australians, free of
clinical cardiovascular disease. This association appeared
to be independent of diabetes mellitus and hypertension.
Future prospective studies are needed to clarify the temporal sequence of this association. As CKD is a predictor
of cardiovascular disease and mortality [27], a corollary
observation in light of our findings is that at least part of
the reported association between plasma homocysteine
and cardiovascular disease and mortality [4–6] may be
mediated by its effect on renal dysfunction.

References
1 US Renal Data System. USRDS 2006 Annual
Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, National
Institutes of Health, National Institute of
Diabetes and Digestive and Kidney Diseases,
2006.
2 National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney
disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39(suppl 1):
S1–S266.
3 Coresh J, Astor BC, Greene T, Eknoyan G,
Levey AS: Prevalence of chronic kidney disease and decreased kidney function in the
adult US population: Third National Health
and Nutrition Examination Survey. Am J
Kidney Dis 2003;41:1–12.
4 Welch GN, Loscalzo J: Homocysteine and
atherothrombosis. N Engl J Med 1998; 338:
1042–1050.

Homocysteine and Kidney Disease

5 Nygard O, Nordrehaug JE, Refsum H, Ueland
PM, Farstad M, Vollset SE: Plasma homocysteine levels and mortality in patients with
coronary artery disease. N Engl J Med 1997;
337:230–236.
6 Bots ML, Launer LJ, Lindemans J, Hoes AW,
Hofman A, Witteman JC, Koudstaal PJ,
Grobbee DE: Homocysteine and short-term
risk of myocardial infarction and stroke in
the elderly: the Rotterdam Study. Arch Intern Med 1999;159:38–44.
7 Elsayed EF, Tighiouart H, Griffith J, Kurth
T, Levey AS, Salem D, Sarnak MJ, Weiner
DE: Cardiovascular disease and subsequent
kidney disease. Arch Intern Med 2007; 167:
1130–1136.
8 Lim U, Cassano PA: Homocysteine and
blood pressure in the Third National Health
and Nutrition Examination Survey, 1988–
1994. Am J Epidemiol 2002;156:1105–1113.

9 Bowman TS, Gaziano JM, Stampfer MJ, Sesso HD: Homocysteine and risk of developing
hypertension in men. J Hum Hypertens
2006;20:631–634.
10 Hsu CY, McCulloch CE, Darbinian J, Go AS,
Iribarren C: Elevated blood pressure and risk
of end-stage renal disease in subjects without
baseline kidney disease. Arch Intern Med
2005;165:923–928.
11 Diamond JR: Analogous pathobiologic
mechanisms in glomerulosclerosis and atherosclerosis. Kidney Int Suppl 1991; 31:S29–
S34.
12 Keane WF, Kasiske BL, O’Donnell MP: Lipids and progressive glomerulosclerosis. A
model analogous to atherosclerosis. Am J
Nephrol 1988; 8:261–271.
13 Remuzzi G, Bertani T: Pathophysiology of
progressive nephropathies. N Engl J Med
1998;339:1448–1456.

Kidney Blood Press Res 2008;31:55–62

61

14 Chen YF, Li PL, Zou AP: Effect of hyperhomocysteinemia on plasma or tissue adenosine levels and renal function. Circulation
2002;106:1275–1281.
15 Ingram AJ, Krepinsky JC, James L, Austin
RC, Tang D, Salapatek AM, Thai K, Scholey
JW: Activation of mesangial cell MAPK in
response to homocysteine. Kidney Int 2004;
66:733–745.
16 Shastry S, Ingram AJ, Scholey JW, James LR:
Homocysteine induces mesangial cell apoptosis via activation of p38-mitogen-activated
protein kinase. Kidney Int 2007;71:304–311.
17 Li N, Chen L, Muh RW, Li PL: Hyperhomocysteinemia associated with decreased renal
transsulfuration activity in Dahl S rats. Hypertension 2006;47:1094–1100.
18 Ninomiya T, Kiyohara Y, Kubo M, Tanizaki
Y, Tanaka K, Okubo K, Nakamura H, Hata J,
Oishi Y, Kato I, Hirakata H, Iida M: Hyperhomocysteinemia and the development of
chronic kidney disease in a general population: the Hisayama study. Am J Kidney Dis
2004;44:437–445.

62

19 Samuelsson O, Lee DM, Attman PO, KnightGibson C, Mullen JK, Larsson R, Mulec H,
Weiss L, Alaupovic P: The plasma levels of
homocysteine are elevated in moderate renal
insufficiency but do not predict the rate of
progression. Nephron 1999;82: 306–311.
20 Sarnak MJ, Wang SR, Beck GJ, Kusek JW,
Selhub J, Greene T, Levey AS: Homocysteine,
cysteine, and B vitamins as predictors of kidney disease progression. Am J Kidney Dis
2002;40:932–939.
21 Chia EM, Wang JJ, Rochtchina E, Smith W,
Cumming RR, Mitchell P: Impact of bilateral visual impairment on health-related
quality of life: the Blue Mountains Eye Study.
Invest Ophthalmol Vis Sci 2004;45:71–76.
22 Nexo E, Engbaek F, Ueland PM, Westby C,
O’Gorman P, Johnston C, Kase BF, Guttormsen AB, Alfheim I, McPartlin J, Smith D,
Moller J, Rasmussen K, Clarke R, Scott JM,
Refsum H: Evaluation of novel assays in clinical chemistry: quantification of plasma total
homocysteine. Clin Chem 2000; 46: 1150–
1156.
23 Shankar A, Wang JJ, Rochtchina E, Mitchell
P: Positive association between plasma fibrinogen level and incident hypertension
among men: population-based cohort study.
Hypertension 2006;48:1043–1049.

Kidney Blood Press Res 2008;31:55–62

24 Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW,
Materson BJ, Oparil S, Wright JT Jr, Roccella
EJ, the National High Blood Pressure Education Program Coordinating Committee:
Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation,
and Treatment of High Blood Pressure. Hypertension 2003;42:1206–1252.
25 Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to
estimate glomerular filtration rate from serum creatinine: a new prediction equation.
Modification of Diet in Renal Disease Study
Group. Ann Intern Med 1999;130:461–470.
26 Friedman AN, Bostom AG, Selhub J, Levey
AS, Rosenberg IH: The kidney and homocysteine metabolism. J Am Soc Nephrol
2001;12:2181–2189.
27 Vanholder R, Massy Z, Argiles A, Spasovski
G, Verbeke F, Lameire N: Chronic kidney
disease as cause of cardiovascular morbidity
and mortality. Nephrol Dial Transplant
2005;20:1048–1056.

Shankar /Wang /Chua /Rochtchina /
Flood /Mitchell

